Skip to main content
Top
Published in: Diabetologia 6/2024

27-02-2024 | Diabetic Retinopathy | Short Communication

Dysregulated 24 h melatonin secretion associated with intrinsically photosensitive retinal ganglion cell function in diabetic retinopathy: a cross-sectional study

Authors: Sirimon Reutrakul, Jason C. Park, J. Jason McAnany, Felix Y. Chau, Kirstie K. Danielson, Bharati Prasad, Andrew Cross, Stephanie Sintetas, Julie Law, Silvana Pannain, Sarida Pratuangtham, Eve Van Cauter, Erin C. Hanlon

Published in: Diabetologia | Issue 6/2024

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to explore whether diabetic retinopathy is associated with alterations of the circadian system, and to examine the role of reduced intrinsically photosensitive retinal ganglion cell (ipRGC) function.

Methods

Participants with type 2 diabetes, with diabetic retinopathy (n=14) and without diabetic retinopathy (n=9) underwent 24 h blood sampling for melatonin and cortisol under controlled laboratory conditions. ipRGC function was inferred from the post-illumination pupil response (PIPR). Habitual sleep duration, efficiency and variability were assessed by actigraphy.

Results

Participants with diabetic retinopathy compared to participants without diabetic retinopathy had smaller PIPR (p=0.007), lower 24 h serum melatonin output (p=0.042) and greater day-to-day sleep variability (p=0.012). By contrast, 24 h cortisol profiles, sleep duration and efficiency were similar in both groups. Six individuals with diabetic retinopathy had no detectable dim-light melatonin onset. PIPR correlated with 24 h mean melatonin levels (r=0.555, p=0.007).

Conclusions/interpretation

ipRCG dysfunction in diabetic retinopathy is associated with disruptions of the 24 h melatonin rhythm, suggesting circadian dysregulation in diabetic retinopathy.

Graphical Abstract

Appendix
Available only for authorised users
Literature
8.
go back to reference Davis MD, Fisher MR, Gangnon RE et al (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 39(2):233–52PubMed Davis MD, Fisher MR, Gangnon RE et al (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 39(2):233–52PubMed
19.
go back to reference Chen W, Cao H, Lu QY et al (2014) Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes. Int J Clin Exp Pathol 7(7):4317–22PubMedPubMedCentral Chen W, Cao H, Lu QY et al (2014) Urinary 6-sulfatoxymelatonin level in diabetic retinopathy patients with type 2 diabetes. Int J Clin Exp Pathol 7(7):4317–22PubMedPubMedCentral
22.
go back to reference Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z (2019) Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr (Edinburgh, Scotland) 38(1):191–6. https://doi.org/10.1016/j.clnu.2017.12.004CrossRef Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z (2019) Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr (Edinburgh, Scotland) 38(1):191–6. https://​doi.​org/​10.​1016/​j.​clnu.​2017.​12.​004CrossRef
Metadata
Title
Dysregulated 24 h melatonin secretion associated with intrinsically photosensitive retinal ganglion cell function in diabetic retinopathy: a cross-sectional study
Authors
Sirimon Reutrakul
Jason C. Park
J. Jason McAnany
Felix Y. Chau
Kirstie K. Danielson
Bharati Prasad
Andrew Cross
Stephanie Sintetas
Julie Law
Silvana Pannain
Sarida Pratuangtham
Eve Van Cauter
Erin C. Hanlon
Publication date
27-02-2024
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 6/2024
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-024-06118-3

Other articles of this Issue 6/2024

Diabetologia 6/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.